Search results for "coxsackievirus B"

showing 10 items of 10 documents

Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells

2018

Aims/hypothesis: The Coxsackie and adenovirus receptor (CAR) is a transmembrane cell-adhesion protein that serves as an entry receptor for enteroviruses and may be essential for their ability to infect cells. Since enteroviral infection of beta cells has been implicated as a factor that could contribute to the development of type 1 diabetes, it is often assumed that CAR is displayed on the surface of human beta cells. However, CAR exists as multiple isoforms and it is not known whether all isoforms subserve similar physiological functions. In the present study, we have determined the profile of CAR isoforms present in human beta cells and monitored the subcellular localisation of the princi…

0301 basic medicineMaleviruksetEndocrinology Diabetes and MetabolismInsulin-Secreting CellsProtein IsoformsReceptorChildProinsulinEnterovirusMicroscopy ConfocalChemistryNuclear ProteinsImmunogold labellingMiddle AgedFlow CytometryImmunohistochemistryTransmembrane protein3. Good healthCell biologyEndocrinologieenteroviruksetMédecine interneProtein interacting with C-kinase 1 (PICK1)medicine.anatomical_structureChild PreschoolCoxsackievirus BFemalePancreasPICK1Gene isoformBeta cells; Coxsackie and adenovirus receptor; Coxsackievirus B; Enterovirus; Insulin granule; Pancreas; Protein interacting with C-kinase 1 (PICK1)AdultCoxsackie and Adenovirus Receptor-Like Membrane ProteinAdolescentImmunoprecipitationBlotting WesterninsuliiniArticle03 medical and health sciencesYoung AdultMétabolismeInternal MedicinemedicineHumansImmunoprecipitationPancreasCoxsackie and adenovirus receptorInsulin granuleDiabétologieBeta cellshaima030104 developmental biologyDiabetes Mellitus Type 1Carrier ProteinsDiabetologia
researchProduct

Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.

2017

Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. Recent studies have also suggested that they may contribute to the development of type 1 diabetes. Vaccination would provide an effective way to prevent CVB infections, and the objective of this study was to develop an efficient vaccine production protocol for the generation of novel CVB vaccines. Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation time, type of cell growth medium, virus purification method and formulation of the purified virus. Safety…

0301 basic medicineformalin inactivationviruksetvirusesDrug Evaluation PreclinicalPolysorbatesmedicine.disease_causeAntibodies ViralMice0302 clinical medicineMultiplicity of infectionImmunogenicity VaccinevaccineChlorocebus aethiops030212 general & internal medicineImmunogenicityVaccinationVaccinationInfectious Diseasescoxsackievirus B1Molecular MedicineFemaleUltracentrifugeVirus CultivationCoxsackievirus InfectionsBiologyCoxsackievirusta3111VirusMicrobiology03 medical and health sciencesFormaldehydemedicineAnimalsCVB1Vero CellscoxsackievirusGeneral VeterinaryGeneral Immunology and Microbiologyrokotteetta1182Public Health Environmental and Occupational HealthViral Vaccinesbiology.organism_classificationVirologyAntibodies NeutralizingVirus CultivationEnterovirus A HumanDisease Models Animal030104 developmental biologyVaccines Inactivatedvirus purificationEnterovirusVaccine
researchProduct

Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

2014

Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and produ…

Viral MyocarditisvirusesIon chromatographyGenetic VectorsCoxsackievirus InfectionsBiologyAntibodies ViralVirus03 medical and health sciencesMice0302 clinical medicineImmune systemVirus-like particleAntibody SpecificityVirologyGene OrderAnimalscardiovascular diseases030212 general & internal medicineVaccines Virus-Like Particle030304 developmental biologyPharmacology0303 health sciencesImmunity Cellularta1182virus diseasesmusculoskeletal systemChromatography Ion ExchangeVirology3. Good healthEnterovirus B HumanVaccinationDisease Models AnimalImmunizationCoxsackievirus b3cardiovascular systemFemaleImmunizationBaculoviridaeAntiviral Research
researchProduct

Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

2020

Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The licensed enterovirus vaccines and those currently in clinical development are traditional inactivated or live attenuated vaccines. Even though these vaccines work well in the prevention of enterovirus diseases, new vaccine technologies, like virus-like particles (VLPs), can offer important advantages in the manufacturing and epitope engineering. We have previously produced VLPs for CVB3 and CVB1 in insect cells. Here, we describe the production of CVB3-VLPs with enhanced pro…

and promotion of well-beingvirusesPROTECTS MICEPOLIOVIRUSCardiovascularcomplex mixturesvirus-like particle (VLP)virus-like particleVaccine RelatedvaccineIMMUNE-RESPONSECoxsackievirus B (CVB)COXSACKIEVIRUS B3lcsh:QH301-705.5PARTICLE VACCINE11832 Microbiology and virologyPreventionrokotteetvirus diseasesMICROSCOPYPrevention of disease and conditionsenteroviruksetHeart DiseaseInfectious DiseasesGood Health and Well Beinglcsh:Biology (General)3.4 VaccinesCoxsackievirus BENTEROVIRUS 71VIRUSImmunization3111 BiomedicineInfectionRECEPTOR-BINDINGB1Biotechnology
researchProduct

Infectious Entry Pathway of Enterovirus B Species

2015

Enterovirus B species (EV-B) are responsible for a vast number of mild and serious acute infections. They are also suspected of remaining in the body, where they cause persistent infections contributing to chronic diseases such as type I diabetes. Recent studies of the infectious entry pathway of these viruses revealed remarkable similarities, including non-clathrin entry of large endosomes originating from the plasma membrane invaginations. Many cellular factors regulating the efficient entry have recently been associated with macropinocytic uptake, such as Rac1, serine/threonine p21-activated kinase (Pak1), actin, Na/H exchanger, phospholipace C (PLC) and protein kinase Cα (PKCα). Another…

coxsackievirus A9EchovirusEndosomelcsh:QR1-502Virus AttachmentEndosomesReviewCoxsackievirusEndocytosismedicine.disease_causelcsh:Microbiology03 medical and health sciencesVirologymedicineReceptorProtein kinase A030304 developmental biology0303 health sciencesbiologyKinase030302 biochemistry & molecular biologyechovirusVirus Internalizationbiology.organism_classificationVirologyEndocytosisEnterovirus B Human3. Good healthCell biologyInfectious DiseasesHost-Pathogen InteractionsEnterovirusentrycoxsackievirus B3signalingViruses
researchProduct

Infectious Entry Pathway of Enterovirus B Species

2015

coxsackievirus A9ta1183echovirusta1182entrycoxsackievirus B3signalingViruses
researchProduct

Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine

2019

Type B Coxsackieviruses (CVBs) are a common cause of acute and chronic myocarditis, dilated cardiomyopathy and aseptic meningitis. However, no CVB-vaccines are available for human use. We have previously produced virus-like particles (VLPs) for CVB3 with a baculovirus-insect cell production system. Here we have explored the potential of a VLP-based vaccine targeting CVB1 and describe the production of CVB1-VLPs with a scalable VLP purification method. The developed purification method consisting of tangential flow filtration and ion exchange chromatography is compatible with industrial scale production. CVB1-VLP vaccine was treated with UV-C or formalin to study whether stability and immuno…

enteroviruksetBiolääketieteet - BiomedicinevirusesvaccinerokotteetCoxsackievirus Bvirus diseasesformaldehydicomplex mixturesformalinvirus-like particle
researchProduct

A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine

2019

Type B Coxsackieviruses (CVBs) belong to the enterovirus genus, and they cause both acute and chronic diseases in humans. CVB infections usually lead to flu-like symptoms but can also result in more serious diseases such as myocarditis, aseptic meningitis and life-threatening multi-organ infections in young infants. Thus, CVBs have long been considered as important targets of future vaccines. We have previously observed CVB1 capsid disintegration and virus concentration decrease with 12-day long formalin inactivation protocol. Here a scalable ion exchange chromatography purification method was developed, and purified CVB1 was inactivated with UV-C or formalin. Virus morphology and concentra…

enteroviruksetcoxsackievirus BBiolääketieteet - Biomedicinerokotteetultraviolettisäteilyinactivated vaccineformaldehydiformalinUV
researchProduct

Development of novel probes for enterovirus B group to study uncoating and infection

2016

Enterovirus B group (EV-B) viruses are important human pathogens which cause a variety of diseases from mild respiratory illnesses to more severe acute infections such as myocarditis and meningitis. EV-Bs have also been associated with chronic infections and autoimmune diseases such as type I diabetes. Because of their significance, better and more accurate methods are necessary to track and visualize viruses in vitro and in vivo. This thesis focus on the development of novel probes to label viruses site-specifically and track infection in vitro. First, we established a covalent conjugation between gold nanocluster markers and EV-B viruses. We were able to visualize through electron microsc…

enteroviruksetvirus trackingviruksetgold nanoclusterhydrophobic pocketmarkkeritcoxsackievirus B1elektronimikroskopiananohiukkasetenterovirus B speciesinfektiotmultivesicular bodykapsidi
researchProduct

The activation of aggresomal pathway in Coxsackievirus B3 infection

2016

Aggresomin muodostuminen on yksi solun puolustusmekanismeista, joka pyrkii estämään proteiinien haitallisen aggregoitumisen solulimassa. Aikaisemmat kokeet ovat näyttäneet, että ihmisen enterovirus-infektio aiheuttaa muutoksia vimentiinissä, tyypin III välikokoisessa filamentissa (Turkki et al., julkaisematon data). Nämä muutokset ovat hyvin samankaltaisia aggresomin muodostumisen aikana tapahtuvien muutoksien kanssa. Tämän tutkimuksen tarkoituksena oli selvittää mahdollisen aggresomin muodostumisreitin aktivoituminen Coxsackievirus B3 (CVB3) -infektiossa, ja hypoteesimme oli, että häkkimäisten vimentiinirakenteiden muodostumisen lisäksi myös muita aggresomin muodostumisreitin aktivoitumise…

vimentiinienteroviruksetvimentinisäntäsolutaggresomeaggresomipuolustusmekanismit (biologia)ER stressCoxsackievirus B3infektiot
researchProduct